Can we establish a hierarchy among trastuzumab biosimilar candidates?

The European patent for intravenous trastuzumab lapsed in 2017, and this stimulated research into a number of trastuzumab biosimilars. Quality assessment of their development and clinical results might enable establishment of a clinical hierarchy of these agents. This editorial will underline the ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivot, Xavier, Petit, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068097/
https://www.ncbi.nlm.nih.gov/pubmed/30002436
http://dx.doi.org/10.1038/s41416-018-0171-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068097/
https://www.ncbi.nlm.nih.gov/pubmed/30002436
http://dx.doi.org/10.1038/s41416-018-0171-1

Ejemplares similares